An endosomolytic cell-penetrating peptide (EB1) and PEG-decorated cationic liposomes both effectively delivered anti-BCR-ABL1 siRNA into chronic myeloid leukemia cells, with liposomes producing more effective gene silencing and growth arrest.
Effective BCR-ABL1 silencingBoth peptide and liposome delivery systems suppressed the leukemia-driving gene in CML cells
What the researchers found
Both EB1 cell-penetrating peptide and PEG-cationic liposomes delivered anti-BCR-ABL1 siRNA into CML K562 cells, with liposomes producing more effective gene silencing and proliferation inhibition.
Why it matters
Drug resistance in CML is a serious clinical problem. Gene-silencing therapy targeting BCR-ABL1 could bypass resistance mechanisms entirely, and developing effective delivery systems is the key barrier to making this approach clinically viable.
The numbers in context
siRNA targeting BCR-ABL1; CPP + cationic liposome delivery system; growth arrest demonstrated in CML cells in vitro.
How the study worked
In vitro study comparing EB1 peptide and 2X3-DOPE-DSPE-PEG2000 liposomes for siRNA delivery into K562 human CML cells. Gene expression and cell proliferation assessed.
Who was studied
Chronic myeloid leukemia cell lines in vitro
What this study cannot tell us
In vitro study in a single CML cell line (K562). No in vivo testing. Liposomes outperformed peptide delivery for this application. Clinical translation requires animal studies for toxicity, distribution, and efficacy. Durability of gene silencing not assessed.
How to read the evidence
Preliminary evidence — in vitro proof-of-concept in a single cell line. Demonstrates feasibility but requires significant preclinical development.
When this study was published
Published in 2024. Contributes to the growing field of peptide-mediated nucleic acid delivery for cancer therapy.
The bigger picture
Cell-penetrating peptides are increasingly important as delivery vehicles for biologics that can't cross cell membranes on their own. While liposomes outperformed in this study, peptide-based delivery offers advantages in targeting and biodegradability that could be optimized for clinical use.
Questions still open
- Can EB1 peptide delivery be optimized to match liposome efficiency?
- Would combining peptide targeting with liposome delivery create a superior system?
- Can this siRNA approach overcome the specific mutations causing tyrosine kinase inhibitor resistance in CML?
Common questions
Can peptides help deliver gene therapy to cancer cells?
Why is it hard to get gene therapy into cells?
Read the original research
Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.
Biochimie, 221, 1-12
Citation
Vysochinskaya, Vera; Zabrodskaya, Yana; Dovbysh, Olesya; Emelyanov, Anton; Klimenko, Vladimir; Knyazev, Nikolay; Terterov, Ivan; Egorova, Marya; Bogdanov, Alexey; Maslov, Michael; Vasin, Andrey; Dubina, Michael. (2024). Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro.. Biochimie, 221, 1-12. https://doi.org/10.1016/j.biochi.2024.01.006